Ladenburg Thalmann Initiates Coverage On Sonoma Pharmaceuticals with Buy Rating, Announces Price Target of $3.25
Portfolio Pulse from Benzinga Newsdesk
Ladenburg Thalmann analyst Jeff Cohen has initiated coverage on Sonoma Pharmaceuticals (NASDAQ:SNOA) with a Buy rating and a price target of $3.25.
September 05, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sonoma Pharmaceuticals has been initiated with a Buy rating by Ladenburg Thalmann, with a price target of $3.25.
The initiation of coverage by Ladenburg Thalmann with a Buy rating and a price target of $3.25 indicates a positive outlook for Sonoma Pharmaceuticals. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100